ArticleEpilepsia open2026
Structural morphometry distinguishes vagus nerve stimulation outcomes in individuals with epilepsy.
Article in Epilepsia open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveVagus nerve stimulation (VNS) is a commonly used treatment for drug-resistant epilepsy. However, response to VNS is variable, while understanding of this response variability is limited. The vagus afferent network (VagAN), the neural circuits thought to be involved in response to vagal afferents, has been implicated in response prediction in modalities such as diffusion-weighted imaging, functional imaging, and neurophysiology. Structural abnormality in the VagAN from T1w MRI has not yet been studied.
methodsWe assessed if VagAN abnormalities, derived from pre-implantation T1w MRI, were associated with VNS response in 92 individuals with epilepsy two years post-implantation (42 responders, 50 non-responders). We used the first principal component (PC1) from a robust principal component analysis for a variety of region sets trained using 100 healthy controls. We investigated two primary hypotheses. (i) If VagAN regions' PC1 differentiates response groups, (ii) if other region sets did not differentiate response groups.
resultsNon-responders had significantly higher VagAN PC1 abnormality scores than both responders ( SIGNIFICANCE: Structural abnormality of VagAN was associated with non-response to VNS. This suggests that volume abnormalities in key VNS regions correlate negatively with reduction of seizures. Abnormalities in other regions, such as the non-VagAN region set, were not associated with VNS response. This metric, when combined with other modalities, may be a useful measure to improve the selection of individuals with drug-resistant epilepsy for VNS therapy. PLAIN LANGUAGE SUMMARY: Vagus nerve stimulation (VNS) is a common treatment for drug-resistant epilepsy; however, it is not always effective. We tested whether volumes of brain regions related to VNS efficacy and found that abnormality within a set of regions known to be affected by VNS related to non-response. No other set of regions showed this effect implying that this set of regions is uniquely placed to determine if someone may respond to VNS. This work supports the idea that VNS efficacy is limited by an individual's brain abnormality and should be considered in further studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.